Rapid Micro Biosystems (RPID)
(Delayed Data from NSDQ)
$0.88 USD
+0.01 (1.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.86 -0.02 (-2.16%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RPID 0.88 +0.01(1.15%)
Will RPID be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RPID based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPID
What's in Store for Cooper Companies (COO) in Q3 Earnings?
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
RPID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
Other News for RPID
Rapid Micro Biosystems to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Morgan Stanley Remains a Hold on Rapid Micro Biosystems (RPID)
Rapid Micro Biosystems Inc (RPID) Q2 2024 Earnings Call Transcript Highlights: Record Revenue ...
Buy Rating Affirmed for Rapid Micro Biosystems Amid Strong Revenue Growth and Strategic Cost-Saving Initiatives
Rapid Micro Biosystems, Inc. (RPID) Q2 2024 Earnings Call Transcript